Bruno Speder
Bruno Speder is Regulatory Affairs Lead at AstriVax Therapeutics, Leuven, Belgium.
JournalThe use of prior knowledge and platform approaches in early vaccine development
This article explores how platform approaches and prior knowledge can be used in the early development of vaccines.
InterviewFAMHP: The role of the Belgian Agency in advancing public health
This interview with Professor Hugues Malonne, Chief Executive Officer of the Belgian Federal Agency for Medicines and Health Products (FAMHP) discusses the Agency’s role in helping shape regulatory affairs and improving health.
JournalArtificial intelligence in drug discovery
The recent publication of papers by the European Medicines Agency (EMA)[1] and the Food and Drug Administration (FDA)[2][3] has spurred the debate on the use of artificial intelligence (AI) in drug development and how it can be used to bring novel compounds to the market.
JournalAccelerated regulatory pathways: Vaccines for tropical diseases
Reproduced from an online seminar presentation, made in collaboration with TOPRA and hVIVO, given on 21 June 2022 by Bruno Speder from hVIVO.